Additionally, our previous study confirmed the anti-hepatofibrotic effects of GF and silymarin via the regulation of hepatic Sirt1 activities using a TAA-induced liver fibrosis model, especially ameliorations of pro-fibrogenic cytokines, decreases in ECMs, and increases in antioxidant effects by regulation of the LKB1/AMPKα/NF-κB signaling pathway [24]. The gene discussed is SIRT1; the disease is Hepatic fibrosis.